BioXcel Therapeutics, Inc.
General ticker "BTAI" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $26.1M (TTM average)
BioXcel Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -18.1%.
Estimated limits based on current volatility of 3.1%: low 1.15$, high 1.23$
Factors to consider:
- Total employees count: 29 (-21.6%) as of 2025
- Top business risk factors: Operational and conduct risks, Transition to commercial activities with unforeseen expenses, Potential disputes with bioxcel LLC, Third-party risks, Labor/talent shortage/retention
- Current price 15.9% below estimated low
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.41$, 5.06$]
- 2026-12-31 to 2027-12-31 estimated range: [0.95$, 3.58$]
Financial Metrics affecting the BTAI estimates:
- Positive: with PPE of -0.3 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of 0 > -0.60
- Negative: negative Net income
Short-term BTAI quotes
Long-term BTAI plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $1.38MM | $2.27MM | $0.64MM |
| Operating Expenses | $173.16MM | $69.51MM | $51.10MM |
| Operating Income | $-171.78MM | $-67.25MM | $-50.46MM |
| Non-Operating Income | $-7.27MM | $7.65MM | $-19.44MM |
| Interest Expense | $13.31MM | $15.13MM | $16.98MM |
| R&D Expense | $84.33MM | $30.43MM | $30.25MM |
| Income(Loss) | $-179.05MM | $-59.60MM | $-69.90MM |
| Net Income(Loss)* | $-179.05MM | $-59.60MM | $-69.90MM |
| Stockholders Equity | $-56.51MM | $-93.10MM | $-95.46MM |
| Inventory | $1.99MM | $0.68MM | $0.72MM |
| Assets | $73.70MM | $38.34MM | $44.92MM |
| Operating Cash Flow | $-155.01MM | $-72.03MM | $-57.62MM |
| Capital expenditure | $0.02MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $-0.02MM | $0.00MM | $0.00MM |
| Financing Cash Flow | $26.52MM | $36.66MM | $56.52MM |
| Earnings Per Share** | $-98.35 | $-23.51 | $-5.73 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.